Authors

Latest:

Dr. Shereck Highlights a Day In the Life of an Attending Physician

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.

John F. Lazar, MD

Latest:

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

IU School of Medicine

Latest:

IU Cancer Researchers Refining Colorectal Cancer Classification, Identifying New Targets for Treatment Using Cutting-Edge, Single-Cell Technology

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

Peter Forsberg, MD

Latest:

Advice for Community Oncologists Treating Patients With R/R MM

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

Kadrin Wilfong, MD

Latest:

Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical Education

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Daniel C. Danila, MD

Latest:

Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Antonia DePace

Latest:

From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Latest:

HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB

Dr Harrington discusses PDS0101 plus pembrolizumab in HPV16+ HNSCC and how the VERSATILE-003 trial may change the HNSCC treatment paradigm.

Dana B Cardin, MD, MSCI

Latest:

Dr Cardin on the Influence of Comorbidities on Treatment Selection in Pancreatic Cancer

Dana B Cardin, MD, MSCI, discusses the importance of identifying comorbidities and high-risk features when determining the optimal treatment approach for patients with pancreatic cancer.

Ruchi Bhatt, DO

Latest:

Dr. Bhatt on the Investigation of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.

Sponsored by Bristol Myers Squibb

Latest:

The Impact of CAR T Cell Therapy on Managing R/R LBCL

CAR T cell therapies have shown remarkable clinical success in difficult-to-treat blood cancers. Read one oncologist’s perspective on what current CAR T therapies may offer patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including at earlier points in their disease journey.

Ismail Jatoi, MD

Latest:

Dr. Jatoi on SLN Biopsy in ER-Positive, HER2-Negative Breast Cancer

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Irene Morae Kang, MD

Latest:

Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

Whitney Goldsberry, MD

Latest:

Dr Goldsberry on the Risk of Secondary Malignancies With PARP Inhibitors in Ovarian Cancer

Whitney Goldsberry, MD, discusses the potential risk of secondary malignancies in patients with ovarian cancer receiving PARP inhibitors.

Doug Smith, MD, John Hopkins Medicine

Latest:

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Namrata (Neena) Vijayvergia, MD

Latest:

Dr. Vijayvergia on the Efficacy of Pembrolizumab in MSI-H Advanced Gastric Cancer

Namrata (Neena) Vijayvergia, MD, discusses the efficacy of pembrolizumab with or without chemotherapy in patients with microsatellite instability–high advanced gastric cancer.

University of Cincinnati Cancer Center

Latest:

New Trial Tests Chemotherapy Regimen Following Pancreatic Cancer Surgery

A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.

Michael Blackman, MD

Latest:

Patient Experiences Can Affect a Practice’s Financial Health

The patient experience is a critical factor in the success of any healthcare practice, and its importance is increasing with the rise of health care consumerism.

Jose Javier Bravo-Cordero, MD

Latest:

Dr. Bravo-Cordero on the Role of the Extracellular Matrix in Breast Cancer Dormancy

Jose Javier Bravo-Cordero, MD, discusses the role of extracellular matrix proteomics and disseminating tumor cells when regulating the tumor microenvironment to induce dormancy in breast cancer.

Evan Lipson, MD

Latest:

Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.